Key Quantitative Figures

The Board of Directors has recommended a Final Dividend of Re. 1.00 per equity share (face value Re. 1) for the Financial Year ended March 31, 2026.

Dates of Action

  • Board Meeting Date: Tuesday, May 12, 2026 (dividend recommendation)
  • Annual General Meeting: Wednesday, July 15, 2026 (shareholder approval required)
  • Record Date: Wednesday, July 08, 2026 (for determining shareholder eligibility)
  • Document Submission Deadline: Wednesday, July 08, 2026 (cut-off for tax documents)
  • Disclosure Date: June 19, 2026

Parties Involved

  • Bliss GVS Pharma Limited (Issuer)
  • National Stock Exchange of India Limited
  • BSE Limited
  • Shareholders (Resident and Non-Resident)
  • Registrar and Share Transfer Agent (RTA)
  • Depository Participants

TDS Provisions for Resident Shareholders

General Rates

  • 10% TDS for shareholders with valid PAN registered with the company
  • 20% TDS for shareholders without PAN/invalid PAN/PAN not linked with Aadhaar

Exemptions for Resident Individuals

  • No TDS if total dividend during FY 2026-27 does not exceed ₹10,000
  • No TDS if shareholder provides valid Form 121 (all eligibility conditions must be met)
  • No TDS if exemption certificate issued by Income-tax Department

Exemptions for Resident Non-Individuals

Specific exemptions require submission of self-declaration and supporting documents for:

  • Insurance Companies (registration with IRDA/LIC/GIC required)
  • Mutual Funds (SEBI registration required)
  • Alternative Investment Funds (Category I or II registered with SEBI)
  • New Pension System Trust
  • Other non-individual shareholders with supporting exemption evidence

TDS Provisions for Non-Resident Shareholders

Domestic Tax Law

  • 20% TDS plus applicable surcharge and cess
  • Lower/NIL rate possible with certificate under Section 395(1)

DTAA Provisions

Non-resident shareholders can opt for DTAA benefits if more beneficial, requiring submission of:

  • Self-attested PAN copy (if allotted)
  • Valid Tax Residency Certificate (TRC) for FY 2026-27
  • Digital Form 41 (mandatory for period April 1, 2026 to March 31, 2027)
  • SEBI registration certificate (for FII/FPI)
  • Self-declaration of treaty eligibility and beneficial ownership
  • Special requirements for Singapore tax residents regarding Article 24 limitation

Additional Provisions

  • Higher TDS rate applied if PAN not linked with Aadhaar as per Section 262
  • Declaration under Rule 203 required if dividend income assessable in hands of person other than deductee
  • For multiple accounts under single PAN, highest applicable tax rate will be applied to entire holding

Submission Procedures

  • All tax-related documents must be submitted to info@blissgvs.com, cs@blissgvs.com, or info@unisec.in
  • Strict deadline of July 8, 2026 - documents received after cutoff may not be considered
  • Documents available for download at https://www.blissgvs.com/tds-on-dividend
  • Company reserves right to verify documents and reject incomplete/discrepant submissions

Payment and Documentation

  • Dividend will be paid after TDS deduction post shareholder approval
  • Soft copy TDS certificate will be issued to email registered with DP/RTA
  • Tax credit can be viewed in Form 168 via TRACES portal or Income Tax e-filing website

Shareholder Requirements

  • Bank account details must be updated in demat accounts/physical folios for dividend credit
  • KYC data (PAN, email, address, mobile) must be current with company/DP
  • Shareholders indemnify company for consequences of misrepresentation in provided information

Disclaimer

The communication is not exhaustive tax advice, and shareholders should consult tax professionals for their specific situations. The company is not obligated to apply beneficial DTAA rates and reserves the right to deduct tax at higher rates in case of document discrepancies.

#Tags: #BlissGVSPharma #Dividend #TDS #SEBIDisclosure #RegulatoryCompliance #Neutral